TY - JOUR
T1 - Enalapril/lercanidipine combination on markers of cardiovascular risk
T2 - A randomized study
AU - Derosa, Giuseppe
AU - Bonaventura, Aldo
AU - Romano, Davide
AU - Bianchi, Lucio
AU - Fogari, Elena
AU - D'Angelo, Angela
AU - Maffioli, Pamela
PY - 2014
Y1 - 2014
N2 - The aim of this study was to evaluate enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to enalapril 20 mg, lercanidipine 10 mg, or enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not enalapril, improved Lp(a) levels compared with baseline, with enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by enalapril/lercanidipine combination compared with enalapril (P
AB - The aim of this study was to evaluate enalapril/lercanidipine combination effects on markers of cardiovascular risk stratification in hypertensive patients. A total of 359 patients were randomized to enalapril 20 mg, lercanidipine 10 mg, or enalapril/lercanidipine 20/10 mg fixed combination. We evaluated blood pressure (BP), fasting plasma glucose (FPG), lipid profile, lipoprotein(a) (Lp[a]), soluble receptor for advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40 L), serum myeloperoxidase (MPO), high sensitivity C-reactive protein (Hs-CRP), and tumor necrosis factor-α (TNF-α). We recorded a decrease of BP in all groups, with the enalapril/lercanidipine combination being more effective in reducing BP compared with single monotherapies. Lipid profile or FPG were not affected by various treatments. Lercanidipine, but not enalapril, improved Lp(a) levels compared with baseline, with enalapril/lercanidipine having a greater effect on Lp(a) reduction. All treatments increased sRAGE levels, and decreased sCD40 L and MPO, even if enalapril/lercanidipine combination was more effective than single monotherapies. TNF-α and Hs-CRP were greater reduced by enalapril/lercanidipine combination compared with enalapril (P
KW - Enalapril
KW - hypertension
KW - lercanidipine
KW - risk factors
UR - http://www.scopus.com/inward/record.url?scp=84903304670&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903304670&partnerID=8YFLogxK
U2 - 10.1016/j.jash.2014.03.329
DO - 10.1016/j.jash.2014.03.329
M3 - Article
C2 - 24836352
AN - SCOPUS:84903304670
VL - 8
SP - 422
EP - 428
JO - Journal of the American Society of Hypertension
JF - Journal of the American Society of Hypertension
SN - 1933-1711
IS - 6
ER -